Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

INKT MiNK Therapeutics, Inc.

NASDAQ

$11.27

MiNK Therapeutics, Inc. (INKT) Earnings News

Earnings press releases and Earnings Whispers previews for MiNK Therapeutics, Inc. (INKT), newest first.

Thursday August 13, 2026 7:30 AM ET

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury

Thursday August 6, 2026 8:19 AM ET

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Friday May 15, 2026 7:30 AM ET

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

Friday May 8, 2026 4:30 PM ET

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Tuesday March 31, 2026 7:30 AM ET

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Tuesday March 17, 2026 7:30 AM ET

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs